The Role of Fibrate Treatment in Dyslipidemia: An Overview
The DOI matches its Crossref record.
Abstract
Dyslipidemia, and especially atherogenic dyslipidemia, a combination of small low-density lipoproteins cholesterol (LDL-C), decreased high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) concentrations, represents a major cardiovascular (CV) risk factor. Nuclear receptor peroxisome proliferator-activated receptors (PPARs) are involved in the regulation of lipid metabolism; PPAR ligands are used to treat dyslipidemias. Fibrates have a major impact on TG metabolism as well as on modulating LDL size and subclasses. Fibrates target atherogenic dyslipidemia by increasing plasma HDL-C concentrations and decreasing small dense LDL (sdLDL) particles and TGs, thus contributing to dyslipidemia management, particularly in patients with diabetes (DM) or the metabolic syndrome (MetS). Furthermore, fibrates exert beneficial effects on adipokines, inflammation and oxidative stress as well as neuroprotective properties. However, further studies are needed to define the role of fibrates in the prevention of CV events. We review the effects of fibrates on atherogenic dyslipidemia and CV risk reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As monotherapy, fibrates likely reduce ASCVD risk.43–45”
From Clinical review on triglycerides (2020) · cites this paper as [44]
Citations
Cites
Still being checked.
Cited by
Non-alcoholic fatty liver disease and dyslipidemia: An update
Katsiki, N., Mikhailidis, D. P., & Mantzoros, C. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.05.003 · Cited by 564
Self-citationClinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
Chalcone Derivatives: Promising Starting Points for Drug Design
Gomes, M., Muratov, E., Pereira, M., Peixoto, J., Rosseto, L., Cravo, P., Andrade, C., & Neves, B. (2017) · Molecules · doi:10.3390/molecules22081210 · Cited by 418
Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome
Legeay, S., Rodier, M., Fillon, L., Faure, S., & Clere, N. (2015) · Nutrients · doi:10.3390/nu7075230 · Cited by 351
Metadata
- Authors
- Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D. P., & Rizzo, M.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-04-01
- Volume
- 19
- Issue
- 17
- Pages
- 3124-3131
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2040713479
- Cited by
- 131
- References
- 0
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 11 · 2023: 10 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 13 · 2015: 13 · 2014: 14 · 2013: 7
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Pharmaceutical Design (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- fibrates, dyslipidemia, atherogenic dyslipidemia, PPAR ligands, small dense LDL, HDL cholesterol, triglycerides, lipid metabolism, cardiovascular risk reduction, diabetes mellitus, metabolic syndrome, adipokines, inflammation, oxidative stress, neuroprotection
- MeSH terms
- Animals, Hypolipidemic Agents, Cardiovascular Diseases, Humans, Cholesterol, LDL, Triglycerides, Dyslipidemias, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of Fibrate Treatment in Dyslipidemia: An Overview. https://app.cochat.ai/papers/10.2174/1381612811319170020
- The paper
- Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D. P., & Rizzo, M. (2013). The Role of Fibrate Treatment in Dyslipidemia: An Overview. Current Pharmaceutical Design. https://doi.org/10.2174/1381612811319170020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.